U.S. Markets open in 50 mins
  • S&P Futures

    3,460.75
    +11.50 (+0.33%)
     
  • Dow Futures

    28,357.00
    +89.00 (+0.31%)
     
  • Nasdaq Futures

    11,686.75
    +37.00 (+0.32%)
     
  • Russell 2000 Futures

    1,640.20
    +9.60 (+0.59%)
     
  • Crude Oil

    40.73
    +0.09 (+0.22%)
     
  • Gold

    1,917.00
    +12.40 (+0.65%)
     
  • Silver

    24.97
    +0.26 (+1.04%)
     
  • EUR/USD

    1.1857
    +0.0031 (+0.2608%)
     
  • 10-Yr Bond

    0.8620
    +0.0140 (+1.65%)
     
  • Vix

    27.66
    -0.99 (-3.46%)
     
  • GBP/USD

    1.3102
    +0.0022 (+0.1690%)
     
  • USD/JPY

    104.7140
    -0.1260 (-0.1202%)
     
  • BTC-USD

    12,956.36
    -10.37 (-0.08%)
     
  • CMC Crypto 200

    261.65
    +5.55 (+2.17%)
     
  • FTSE 100

    5,872.40
    +86.75 (+1.50%)
     
  • Nikkei 225

    23,516.59
    +42.32 (+0.18%)
     

IGM Biosciences to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 26, 2020

MOUNTAIN VIEW, Calif., March 19, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and year-end 2019 financial results on Thursday, March 26, 2020.

In connection with the earnings release, IGM’s management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, March 26, 2020, to discuss the Company’s financial results and provide a corporate update.

Conference ID: 2991398
Domestic Dial-in Number: (866) 649-1996
International Dial-in Number: (409) 217-8769
Live Webcast: https://edge.media-server.com/mmc/p/vw87ve5n

A replay of the audio webcast will be available for 30 days on the Investors section of the Company's website, www.igmbio.com.

About IGM Biosciences, Inc.
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com